1) To determine if 5 doses of Epo (Erythropoietin) 1000 U/kg (birth weight) intravenous (IV) reduces the rate of death or neurodevelopmental impairment (mild, moderate, or severe) at 24 months of age.
2) To assess safety of Epo.
3) To determine whether Epo decreases the severity of HIE-induced brain injury as evidenced by early MRI and plasma biomarkers of brain injury.
We are interested in observing whether and how infants learn when interacting with a robot during a learning assessment contingency paradigm.
Our goal is early identification of deviation from healthy brain development to allow targeted early intervention and improve developmental outcomes.
The collection of the research data we hope will help better screening, diagnosing procedures and treatment of brain injury in newborns and identify a connection between MR imaging and neurodevelopmental outcomes.
To test a new experimental drug Temisirolimus - Temsirolimus (also known as Torisel®) is approved for kidney cell cancer treatment in adults - in combination with approved chemotherapy drugs - in the hopes of finding a drug combination that may be effective against leukemia and non-hodgkin’s lymphoma that has come back after initial treatment. To find the highest dose that can be given without casing severe side effects.
This research is being done to test the safety and effectiveness of intranasal carbetocin to treat Prader Willi Syndrome.
Our purpose is to look at the long-term neurodevelopmental outcomes of preterm neonatal brain abnormalities.
Carfilzomib (also known as Kyprolis®) is approved to be used in certain adult patients with relapsed or refractory multiple myeloma (myeloma that returns after a successful course of treatment or myeloma that does not respond to treatment). Multiple myeloma is a type of blood cancer. Carfilzomib is not approved to treat ALL. It has not been given in combination with the other drugs used in this study. This study is being done to find out if carfilzomib can be safely given before and during treatment with standard chemotherapy drugs.
The goals of this study are to improve survival rates in children and young adults with relapsed AML through the combination of DEC and VOR.
This study aims to evaluate the side effects (good and bad) of giving Vincristine Suflate Liposome Infection (also known as Marqibo®) - a drug approved for leukemia treatment in adults but that is experimental in children - with other standard chemotherapy drugs and to measure how effective the combination is at treating children and young adults with leukemia that has come back after initial treatment.
